Literature DB >> 7513716

Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex.

P Bang1, K Brismar, R G Rosenfeld.   

Abstract

Insulin-like growth factor-I (IGF-I) in serum is predominantly bound in a ternary complex, consisting of IGF peptide, IGF-binding protein-3 (IGFBP-3), and an acid-labile subunit, or a binary complex, consisting of IGF peptide and any of the six IGFBPs. In the binary complex, IGF-I is more bioavailable and has a faster turnover rate. Proteolysis of IGFBP-3 may alter the distribution of IGF-I between these complexes by reducing IGFBP-3 affinity for IGF-I and/or acid-labile subunit and may offer an additional mechanism for regulation of IGF availability. In the present study, sera from patients with noninsulin-dependent diabetes mellitus (NIDDM) were found to have significantly higher IGFBP-3 proteolytic activity than sera from age-matched healthy subjects (188 +/- 12% vs. 104 +/- 6% of a control serum pool; P < 0.001). The mean (+/- SE) of serum IGFBP-3 levels determined by Western ligand blotting was lower in NIDDM patients than in healthy control subjects (61.5 +/- 5% and 79 +/- 5% of a control serum pool, respectively; P < 0.01). However, IGFBP-3 concentrations determined by RIA did not differ. This discrepancy could be explained by IGFBP-3 proteolysis, resulting in IGFBP-3 fragments that are detectable by RIA, but not by Western ligand blotting. Western immunoblotting of sera with or without prior treatment with endoglycosidase-F demonstrated that a glycosylated 29-kilodalton (kDa) IGFBP-3 form with a protein core of 20 kDa was present in sera from healthy controls, and this fragment was increased in NIDDM and term pregnancy sera, suggesting that it is produced by endogenous proteolysis. The presence of the 29-kDa IGFBP-3 proteolytic fragment at about 130-150 kDa after neutral size chromatography of pooled sera may suggest that 29-kDa IGFBP-3 participates in ternary complex formation. Further studies are required to determine whether the avidity of ternary complex formation with the 29-kDa IGFBP-3 fragment is reduced and whether the resulting increased IGF turnover can explain the reduced IGF-I levels (z scores) observed in NIDDM patients compared to healthy subjects (-0.81 +/- 0.32 SD vs. +0.26 +/- 0.17 SD; P < 0.001). Neutral size-chromatography of sera demonstrated that IGFBP-3 protease activity in the approximately 130- to 150-kDa mol wt range is regulated by NIDDM and pregnancy in parallel with that of unfractionated sera.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513716     DOI: 10.1210/jcem.78.5.7513716

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Evidence of a role for insulin-like growth factor binding protein (IGFBP)-3 in metabolic regulation.

Authors:  P M Yamada; H H Mehta; D Hwang; K P Roos; A L Hevener; K W Lee
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

Review 2.  Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.

Authors:  David R Clemmons
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

3.  Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction.

Authors:  M Wallander; K Brismar; J Ohrvik; L Rydén; A Norhammar
Journal:  Diabetologia       Date:  2006-08-29       Impact factor: 10.122

4.  Collection of blood in heparinized tubes does not alter the molecular distribution or forms of IGFBP-3 and IGF.

Authors:  S Mandel; E Moreland; R G Rosenfeld; S E Gargosky
Journal:  Endocrine       Date:  1996-08       Impact factor: 3.633

5.  DNA-PK phosphorylation of IGFBP-3 is required to prevent apoptosis in retinal endothelial cells cultured in high glucose.

Authors:  Qiuhua Zhang; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-30       Impact factor: 4.799

6.  Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly.

Authors:  A J Varewijck; J A M J L Janssen; M Vähätalo; L J Hofland; S W J Lamberts; H Yki-Järvinen
Journal:  Diabetologia       Date:  2012-01-10       Impact factor: 10.122

Review 7.  Role of insulin-like growth factor binding protein-3 in glucose and lipid metabolism.

Authors:  Ho-Seong Kim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2013-03-31

8.  Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men.

Authors:  Satoshi Teramukai; Thomas Rohan; Kyong-Yeon Lee; Hiroyuki Eguchi; Takashi Oda; Suminori Kono
Journal:  Jpn J Cancer Res       Date:  2002-11

9.  IGFBP-3 inhibits cytokine-induced insulin resistance and early manifestations of atherosclerosis.

Authors:  Lathika Mohanraj; Ho-Seong Kim; Wei Li; Qing Cai; Ki Eun Kim; Hye-Jung Shin; Yong-Jae Lee; Woo Jung Lee; Jung Hyun Kim; Youngman Oh
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

Review 10.  Insulin-like growth factor-1 deficiency and metabolic syndrome.

Authors:  G A Aguirre; J Rodríguez De Ita; R G de la Garza; I Castilla-Cortazar
Journal:  J Transl Med       Date:  2016-01-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.